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ABSTRACT
Introduction: Single-pill combination (SPC)
therapy of two drugs is recommended by
international guidelines, including the
Chinese guidelines (2010), for the treatment of
hypertension in high-risk patients who require
marked blood pressure (BP) reductions. Real-
world data on the efficacy and safety of
valsartan/amlodipine (Val/Aml) SPC are scarce.
The present study is the first observational study
in China to evaluate the efficacy (primary
endpoint) and safety of Val/Aml (80/5 mg) SPC
in Chinese patients with hypertension whose
BP was not adequately controlled by
monotherapy in a real-world setting.
Methods: This prospective, multicenter, open-
label, post-marketing observational study
included 11,422 Chinese adults (C18 years)
with essential hypertension from 238 sites of
29 provinces who were prescribed once-daily
Val/Aml (80/5 mg) SPC. Patients were treated
for 8 weeks. The primary efficacy variable of the
study included changes in mean sitting systolic
BP (MSSBP) and mean diastolic BP (MSDBP)
from baseline to week 8 (end point). The
secondary efficacy variable of the study
included BP control rate and response rate at
week 4 and 8. Safety assessments included
recording and measurement of all adverse
events (AEs) and vital signs in the safety
population.
Results: A significant reduction of 27.1 mmHg
in MSSBP (159.6 vs. 132.5 mmHg; P\0.0001)
and 15.2 mmHg in MSDBP (95.6 vs.
80.4 mmHg; P\0.0001) from baseline was
observed at week 8. The BP-lowering efficacy
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of Val/Aml SPC was independent of age and
comorbidities. BP control of \140/90 mmHg
was achieved in 76.8% (n = 8,692) of the
patients. The most frequently reported AEs
were dizziness (0.2%), headache (0.2%), upper
respiratory tract infection (0.2%), and edema
(0.2%). Only three serious AEs were reported
and they were not drug-related.
Conclusion: This is the first evidence-based
real-world data in Chinese hypertensive
patients which demonstrate the efficacy and
safety of Val/Aml (80/5 mg) SPC.




Hypertension, an important risk factor for
cardiovascular diseases (CVDs), affected an
estimated one billion people worldwide in
2000 [1, 2]. This number is expected to rise to
1.56 billion by 2025 [1]. In China, hypertension
is the leading preventable risk factor for
premature mortality [3]. The majority of
cardiovascular (CV) deaths in China were
attributed to hypertension (2.11 million) in
2005 [3]. The China National Nutrition and
Health Survey findings indicated that nearly 0.2
billion (18%) adults in 2002 had hypertension
and only 6.1% of them achieved blood pressure
(BP) control [4]. In 2010, a survey conducted
among Chinese adults aged C18 years revealed
that the prevalence of hypertension was 33.5%
[5].
According to the Chinese guidelines (2010)
for the management of hypertension, a
reduction in systolic BP (SBP) and diastolic BP
(DBP) less than 140/90 mmHg in all
hypertensive patients, and less than
130/80 mmHg in patients with concomitant
diabetes or chronic kidney disease (CKD) is
essential to reduce the risk of CV mortality [6].
However, evidence from a previous study
suggests that only a small proportion of the
hypertensive population in China receives
adequate treatment or achieves effective BP
control [7].
Single-drug therapy or monotherapy is the
preferred way to initiate hypertension
treatment, but BP goals (\140/90 mmHg)
cannot always be achieved with single-drug
therapy in patients who require strong BP
reductions [8, 9]. It has been proposed that in
high-risk hypertensive patients who require a
rapid and pronounced BP control, single-pill
combination (SPC) or fixed-dose combination
can be beneficial as a first-line therapy [10].
SPCs offer several advantages such as improved
efficacy, reduced adverse events (AEs), and
improved patient compliance compared with
monotherapy [8]. Safe and effective
combination of two or more drug classes is
recommended for the majority of patients with
hypertension to achieve their BP goal, which
may translate into reduced risk of CV outcomes
[8–14]. The 2013 European Society of
Hypertension/European Society of Cardiology
Guidelines for the management of arterial
hypertension recommend the initiation of
hypertension treatment with a combination of
two drugs from different classes in patients with
stage 2 hypertension (SBP C160 mmHg or DBP
C100 mmHg) [15]. Moreover, use of an
antihypertensive drug combination in a single
pill may further enhance BP control by reducing
pill burden and enhancing compliance [8, 16].
Amlodipine (Aml) and valsartan (Val) are
widely used antihypertensive drugs that have
also been established to improve CV/renal
outcomes [17, 18]. The combination of Val
and Aml has shown an additive BP-lowering
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effect and minimal AEs in adult patients with
mild-to-moderate hypertension compared to
individual monotherapies [13, 14, 19]. The
efficacy and safety of this combination have
also been demonstrated in the Chinese
population through randomized controlled
clinical trials [20–22]. Two of these studies
evaluated SPC therapy and showed that it
provided better outcomes in terms of efficacy,
safety, and tolerability in Chinese patients
compared with monotherapy [20, 21].
However, the effectiveness of Val/Aml SPC
therapy has not been evaluated in real-world
conditions in China. The present observational
study was conducted to evaluate the
effectiveness and safety of the Val (80 mg) and
Aml (5 mg) SPC therapy on BP control at week 8
in a population of Chinese patients with
uncontrolled BP on antihypertensive
monotherapy in a real-life practice setting.
METHODS
Study Design
This was a multicenter, post-marketing,
prospective observational study enrolled adult
patients with essential hypertension, whose BP
was not adequately controlled by monotherapy.
Patients from 238 regional centers across 29
provinces of China were enrolled from October
12, 2010 to February 20, 2012. The Val/Aml (80/
5 mg) SPC once-daily dosing was prescribed to
the patients instead of the previous
antihypertensive drugs. The treatment was in
compliance with the routine clinical outpatient
practice in China. The duration of the study was
8 weeks with a follow-up at every 4 weeks. If a
patient did not achieve BP control at the end of
4 weeks, an additional antihypertensive agent
could be added.
Study Population
The study population included adult Chinese
patients with essential hypertension [(mean
sitting SBP (MSSBP) C140 mmHg (C130 mmHg
for diabetes or CKD) and/or mean sitting DBP
(MSDBP) C90 mmHg) (C80 mmHg for diabetes
or CKD)], whose BP was not adequately
controlled by monotherapy as mentioned in
the Val/Aml package insert approved by the
State Food and Drug Administration.
Patients were selected based on the following
inclusion criteria: male or female aged
C18 years with essential hypertension; on oral
antihypertensive monotherapy (angiotensin-
converting enzyme inhibitors (ACEIs),
angiotensin-II receptor blockers (ARBs),
calcium channel blockers (CCBs), diuretics, or
b-blockers); MSSBP C140 mmHg and/or MSDBP
C90 mmHg; with diabetes or CKD, MSSBP
C130 mmHg and/or MSDBP C80 mmHg.
Patients were prescribed the Val/Aml SPC
based on the clinical judgment of the
investigators according to the patient’s
condition and taking into consideration the
package insert; signed informed consent was
obtained for all patients. The exclusion criteria
included women who were pregnant or
lactating and or of child-bearing potential
without adequate contraception measures, and
or any other conditions which precluded
administration of the drug based on the
investigator’s discretion.
Patient demographics, history of
hypertension, past medical history and present
complications, BP measure, present
monotherapy, and the reason for switching
medication were recorded for all the
participants during the initial visit.
The study was conducted in accordance
with the International Conference on
Harmonization-Good Clinical Practice
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(ICH-GCP) and applicable local regulations in
China. The study received approval from the
Ethical Review Committee of The First Hospital
of Harbin Medical University. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1975, as revised in 2000 and 2008. Informed
consent was obtained from all patients for being
included in the study.
Efficacy Assessments
The primary efficacy variable of the study
included changes in MSSBP and MSDBP from
baseline to week 8 (end point). The secondary
efficacy variable of the study included BP
control rate and response rate (defined as the
percentage of patients achieving MSSBP
\140 mmHg or MSSBP reduction C20 mmHg
from baseline; MSDBP \90 mmHg or MSDBP
reduction C10 mmHg from baseline) at week 4
and 8. A subgroup analysis of the reduction in
MSSBP and MSDBP values from baseline was
performed at week 8 based on age (\65, 65–\80,
C80), baseline SBP (\140, 140–159, 160–179,
C180), different CV risk factors (dyslipidemia,
coronary heart disease, diabetes, heart failure
(HF), stroke, and kidney disease), and
antihypertensive treatments (ACEIs, ARBs, b
blockers, CCBs, and diuretics).
Safety Assessments
Safety assessments included recording and
measurement of all AEs and vital signs in the
safety population. The incidence of AEs was
recorded at week 4 and 8 of the study period.
Each AE was defined by its duration, severity,
and relationship to the study drug.
Statistical Analysis
Full analysis set (FAS) included patients with at
least one post-baseline efficacy evaluation, and
safety set (SS) included patients with at least one
post-baseline safety evaluation. The FAS was
used for all efficacy analyses. All statistical
analyses were performed using SAS Software
version 9.2 (SAS Institute Inc., Cary, NC, USA) at
two-sided significance level (P) of \0.05.
Demographic and baseline variables were
summarized using descriptive statistics,
including the mean, standard deviation (SD),
median, minimum and maximum values for
numeric variables, and the count number and
percentage for categorical variables. Paired t test,
two-way analysis of variance, the Chi square
test, and logistic regression were used to analyze
efficacy end points. The BP control rates and
medication compliance among subgroups was
analyzed using Chi square test and Wilcoxon
rank-sum test, respectively. AEs were
summarized by incidence rates (frequencies
and percentages). The efficacy, tolerability, and
medication compliance of the SPC evaluated by
the investigator and the patient were classified
as ‘very good’, ‘good’, ‘general’, and ‘not good’.
RESULTS
Demographic and Baseline Characteristics
A total of 11,422 patients were enrolled for the
study, of which 27 patients were excluded for
violating GCP, 71 patients did not meet the
inclusion criteria, and 63 patients withdrew.
Finally, 11,312 patients were included in the
FAS, and 11,321 patients in the SS (Fig. 1). The
detailed demographic and baseline
characteristics of the patients are presented in
Table 1. The mean age of the patients included
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in the FAS was 58.4 years. Approximately 57% of
the patients were male; and 97.1% of the
patients belonged to the Han ethnic group.
The mean duration of hypertension was
8.3 ± 7.3 years with a mean baseline SBP/DBP
value of 159.6/95.6 mmHg. A large proportion
of the patients in this study had hypertension
without any other CV risk factors (36.9%;
n = 4,174).
CCB (47.9%; n = 5,413) was the most
commonly used monotherapy prior to
enrollment, followed by ARB (25.2%;
n = 2,853) and ACEI (15.3%; n = 1,728). The
most frequent reasons for switching to SPC
included patients unable to achieve BP goals on
either the initial or titrated dose of
monotherapy (82.0% and 15.0%, respectively),




Val/Aml SPC resulted in a significant reduction
in MSSBP by 20.1 mmHg from baseline after
4 weeks (159.6 vs. 139.5 mmHg; P\0.0001)
and 27.1 mmHg after 8 weeks (159.6 vs.
132.5 mmHg; P\0.0001) of treatment. In
addition, a significant reduction in MSDBP by
10.6 mmHg from baseline after 4 weeks (95.6 vs.
Fig. 1 Patient ﬂow chart. BP blood pressure
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85.0 mmHg; P\0.0001) and 15.2 mmHg after
8 weeks (95.6 vs. 80.4 mmHg; P\0.0001) of
treatment was also noted (Fig. 2).
Table 1 Demographic and baseline characteristics of the
patients (n = 11,312)
Variable Baseline values
Age (years)
Mean age (SD) 58.4 (13.8)






Mean height (SD), cm 167.15 (7.8)
Mean weight (SD), kg 69.18 (11.4)






Mean BMI (SD) 24.7 (3.2)
Patients in each group, n (%)
Underweight (BMI\19) 266 (2.4)
Normal (19 B BMI\24) 4,449 (39.3)
Overweight (24 B BMI\28) 5,127 (45.3)
Obese (BMI[28) 1,447 (12.8)






Kidney disease 355 (3.1)
BP data (mmHg)
Mean baseline SBP 159.6
Mean baseline DBP 95.6
Fig. 2 Reduction in mean systolic and diastolic BP after 4
and 8 weeks of valsartan/amlodipine single-pill
combination treatment. *P\0.0001 vs. baseline. Error
bars represent standard deviation. BP blood pressure,
MSDBP mean sitting diastolic blood pressure, MSSBP
mean sitting systolic blood pressure
Table 1 continued
Variable Baseline values













ACEIs angiotensin-converting enzyme inhibitors, ARBs
angiotensin-II receptor blockers, BMI body mass index, BP
blood pressure, CCBs calcium channel blockers, CHD
chronic heart disease, DBP diastolic blood pressure, HF
heart failure, SBP systolic blood pressure
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Efficacy in Different Subgroups
The patients were grouped based on their age as
\65 years, 65–\80 years, and C80 years. The
mean BP-lowering efficacy of Val/Aml SPC was
independent of age (Fig. 3). Another subgroup
analysis based on baseline SBP levels (i.e., SBP
\140, 140–159, 160–179, and C180 mmHg)
showed significant reductions in MSSBP and
MSDBP (P\0.0001) from baseline in all the
baseline SBP groups after 8 weeks of treatment
(Fig. 4). The mean BP reduction increased with
an increase in baseline SBP levels.
The mean reduction in MSSBP from baseline
at week 8 in patients treated with Val/Aml from
the different antihypertensive monotherapy
groups, namely, b blockers, CCBs, ACEIs,
diuretics, ARBs, and others, was 28.3, 27.3,
28.1, 27.4, 25.7, and 31.9 mmHg, respectively
(Fig. 5). Reduction in MSDBP was also achieved
in the different monotherapy groups after
8 weeks of treatment. As depicted in Fig. 6,
after 8 weeks of SPC treatment, the mean
reduction in MSSBP and MSDBP was also
observed in the subgroups with different CV
risk factors.
Secondary Efficacy
A BP control of\140/90 mmHg was achieved in
76.8% (n = 8,692) of patients after 8 weeks of
Val/Aml SPC treatment. After 8 weeks of
treatment, 98.0% of patients (n = 11,084)
responded to treatment. Of the 11,312
patients in this study, only 686 (6.1%) patients
required add-on therapy at 4 weeks in addition
to the Val/Aml SPC treatment. Diuretics were
the most frequently used add-on therapy during
the study, and 14 patients added 2 additional
antihypertensive drugs.
Safety
The SS consisted of 11,321 patients. The most
frequently reported AEs were dizziness (0.2%),
headache (0.2%), upper respiratory tract
infection (0.2%), and edema (0.2%; Table 2).
Only three serious AEs were reported during the
study; none of them were suspected to be related
to the treatment. The tolerability of Val/Aml
SPC as evaluated by investigators and patients
was quite similar; both evaluations were rated as
‘very good’ by 63.3% (n = 7,170) and 61.3%
Fig. 3 MSSBP and MSDBP reduction in different age
groups at week 8. *P\0.0001 vs. baseline. Error bars
represent standard deviation. BP blood pressure, MSDBP
mean sitting diastolic blood pressure, MSSBP mean sitting
systolic blood pressure
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(n = 6,942), respectively. According to the
investigators’ report, 86.9% (9,787 of 11,266)
of the patients had a high adherence rate of 80%
or greater while taking the Val/Aml SPC.
DISCUSSION
The present study is the first evidence-based,
multicenter, observational real-world study that
demonstrates the effectiveness and safety of
Val/Aml SPC in reducing BP in a very large
number of Chinese hypertensive patients. This
study also showed that Val/Aml SPC was well
tolerated with a good safety profile, even in
patients aged 80 years and older (safety data not
presented by age group). The prevalence rate of
hypertension is on the rise in China, due to lack
of awareness and treatment in addition to
Fig. 4 MSSBP and MSDBP reduction in different baseline
SBP subgroups at week 8. *P\0.0001 vs. baseline. Error
bars represent standard deviation. BP blood pressure,
MSDBP mean sitting diastolic blood pressure, MSSBP
mean sitting systolic blood pressure, SBP systolic blood
pressure
Fig. 5 Mean MSSBP and MSDBP reduction in different
monotherapy subgroups at week 8. *P\0.0001 vs. baseline.
ACEI ace inhibitor, ARB angiotensin receptor blocker, BP
blood pressure, CCB calcium channel blocker, MSDBP
mean sitting diastolic blood pressure, MSSBP mean sitting
systolic blood pressure
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inadequate control of the disease [7]. Various
randomized clinical trials (RCTs) have studied
the efficacy and safety of Val/Aml SPC in the
Chinese population with essential hypertension
[20, 22, 23]. However, most RCTs exclude
patients with very high BP and those with a
risk of CVD and hence, do not represent
findings from actual clinical practice [24]. In
this observational study, patients with SBP
C180 mmHg, and also those with different CV
risk factors were included. Moreover, large
observational studies allow the enrollment of
an adequate number of patients for subgroup
analyses.
Monotherapy is a rational therapeutic
approach in patients with mild CV risk or
mild BP elevation [25]. However, in about 70%
of patients, it is ineffective in achieving BP goals
[25]. The use of combination therapy having
complementary mechanisms of action is more
effective than single agents in achieving
optimal BP control [8, 26]. A SPC of Val and
Aml has been well tolerated regardless of age,
sex, race, or ethnicity [27, 28]. The safety and
efficacy of this combination have also been
demonstrated in RCTs of Chinese individuals
[20, 21]. In the present observational study, SPC
therapy with Val and Aml resulted in significant
reductions in MSSBP and MSDBP from baseline
after 8 weeks, consistent with results of
randomized controlled studies, including those
Fig. 6 MSSBP and MSDBP reduction in subgroups with
different cardiovascular risk factors at week 8. *P\0.0001
vs. baseline. BP blood pressure, CHD coronary heart
disease, HF heart failure, MSDBP mean sitting diastolic
blood pressure,MSSBP mean sitting systolic blood pressure,
SBP systolic blood pressure, UH uncomplicated
hypertension
Table 2 Incidence of adverse events
Variable Patients
(n5 11,321)
Any AE, n (%) 164 (1.4)
Any SAE, n (%) 3 (\0.1)
AE related to treatment, n (%) 64 (0.6)
SAE related to treatment, n (%) 0 (0.0)
Discontinuations due to AEs, n (%) 22 (0.2)




Upper respiratory tract infection 18 (0.2)
Cough 9 (0.1)
AE adverse event, SAE serious adverse event
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conducted in Chinese patients [20–23, 29–33].
After 8 weeks of treatment, BP control (\140/
90 mmHg) with Val/Aml combination was
achieved in approximately 77% of the
patients. This is similar to the significant BP
control rate (72.7%) observed in a broad
spectrum of patients from eight countries
(France, Spain, Belgium, Norway, Switzerland,
Slovakia, Canada, and The United States) whose
BP was initially uncontrolled by monotherapy
and who were switched to Val/Aml 160/10 mg
or 160/5 mg [31]. Likewise, another randomized
controlled study in a general Asian population
reported similar BP control rates (69.2%) in
patients treated with Val/Aml SPC (80/5 mg)
[22]. Our findings support the efficacy of the
Val/Aml (80/5 mg) SPC in a real-world scenario
as well.
SPC therapies improve medication
adherence due to reduced pill burden [8, 34].
In this study, as reported by the patients, more
than 85% of patients took 80% or more of the
Val/Aml SPC, which could be one of the reasons
for improved efficacy. This reinforces the fact
that SPC therapy could improve adherence,
which is an important factor that influences
BP-lowering efficacy of the drug [35].
Combination therapy has the potential for
attenuation of certain drug class—specific AEs
[2]. Val/Aml SPC was well tolerated in this
study. There was a low incidence of AEs
reported in each treatment phase, with three
serious AEs occurring; none of them was
suspected to be related to study treatment. A
common AE of CCBs is peripheral edema which
occurs due to arteriolar dilatation, causing
intracapillary hypertension and fluid
extravasation [36]. Despite the use of a CCB
(i.e., Aml) in the treatment phase, the incidence
of peripheral edema was low with the SPC
treatment. This may be attributed to a short
observational period, a different dose, or
minimization of CCB-induced edema by the
ARB (i.e., Val) [2]. Likewise, a randomized
controlled 8-week study of 349 Asian
hypertensive patients (predominantly Chinese)
treated with Val/Aml 80/5 reported no
incidences of peripheral edema [22] and a
similar study of 308 Asian patients reported a
1.3% incidence [23].
In this study, treatment was effective
regardless of baseline BP, comorbidities,
monotherapy, or age. Elderly patients with
hypertension are at an increased risk of
adverse CVD outcomes such as HF and stroke
[37]. Therefore, effective lowering of BP in the
elderly is clinically very important. Clinical
trials very rarely recruit from the elderly
population, however, in the present
observational study, a sufficient number of
elderly patients over 80 years of age (n = 746)
were included. In this study, after 8 weeks of
Val/Aml SPC treatment reported significant
reductions in BP in elderly patients. A recent
RCT involving 61 Chinese elderly patients has
also shown the efficacy of the Val/Aml
combination therapy in lowering BP in the
elderly population [38].
A limitation of the study design was the
addition of Val/Aml onto other
antihypertensive monotherapies at week 0 or
another antihypertensive drug added onto Val/
Aml at week 4 (when BP cannot be controlled),
which might have contributed to increased
efficacy of the treatment, although the impact
of this has not been determined. This study
observed a low incidence of AEs compared to
several randomized trials with the same SPC,
which may be attributed to the shorter
treatment period of 8-weeks [13, 14].
Alternatively, it is possible that inadequate
communication between the investigator and
the patient could have resulted in non-recording
of events and hence the low incidence of AEs.
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CONCLUSION
In conclusion, the findings from the first real-
world observational study in Chinese
hypertensive patients confirm the effectiveness
and safety of using SPC Val and Aml in a large
population. By initiating treatment with this
combination, significant and early reductions
in both MSSBP and MSDBP were achieved,
which enabled a large proportion of the
patients to reach a BP goal of 140/90 mmHg in
8 weeks. The outcomes of this SPC were found
to be safe and tolerable with low incidences of
AEs in a wide range of Chinese patients with
uncontrolled BP on monotherapy. Additional
studies of longer durations are necessary to
investigate the potential clinical benefits of this
SPC on organ protection and CV outcome
improvement.
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Wang, Guoli Wang, Hongmei Li, Ruiping
Zhao, Junming Liu, Xianjun Xue, Hengliang
Wang, Hao Wang, Zhigang Zhao, Chuanyu
Gao, Chen Lei, Xinjuan Xu, Xiaohong Sang,
Yulan Zhao, Ye Gu, Youzhi Hu, Yulong Shi,
Yongcheng Li, Fafei Zheng, Linqun Hu,
Xiaoming Lin, Yong Zhang, Bei Cheng, Bihui
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Cuntai Zhang, Wuwang Fang, Ting Jiang, Bo
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